IL-18-producing Salmonella inhibit tumor growth

Cancer Gene Therapy

Volumn 15, Issue 12, 2008, Pages 787-794

  Loeffler, M ^a   Le'Negrate, G ^a   Krajewska, M ^a   Reed, J C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Bacterial therapy; Cancer therapy; IL 18; Salmonella; Tumor targeting

Indexed keywords

CYTOKINE; INTERLEUKIN 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOCOMPETENCE; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; T LYMPHOCYTE;

ANIMALS; CYTOKINES; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-18; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEOPLASMS; PROTEIN ENGINEERING; SALMONELLA; TUMOR CELLS, CULTURED;

BACTERIA (MICROORGANISMS); MURINAE; MUS; SALMONELLA; SALMONELLA TYPHIMURIUM;

EID: 56049102354     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.48     Document Type: Article

References (29)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop 1893; 262: 3-11.
2. Coley W. Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigosus. Am J Med Sci 1906; 131: 375-430.
3. Coley W. Melanotic cancer. Ann Surg 1916; 64: 206-241.
4. Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 762-765.
5. Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O'Donnell MA et al. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 1998; 159: 1054-1063.
6. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000; 181: 1996-2002.
7. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-225.
8. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142-152.
9. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-320.
10. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005; 11: 4827-4834.
11. Carrier MJ, Chatfield SN, Dougan G, Nowicka UT, O'Callaghan D, Beesley JE et al. Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol 1992; 148: 1176-1181.
12. Marwick C. FDA halts gene therapy trials after leukaemia case in France. Bmj 2003; 326: 181.
13. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
14. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
15. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y et al. IFN-gamma-inducing factor upregulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157: 3967-3973.
16. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-474.
17. Wigginton JM, Lee JK, Wiltrout TA, Alvord WG, Hixon JA, Subleski J et al. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002; 169: 4467-4474.
18. Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, Kurimoto M et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 1999; 6: 808-815.
19. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. Faseb J 1999; 13: 2195-2202.
20. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997; 57: 4557-4563.
21. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 583-589.
22. Woldbaek PR, Sande JB, Strømme TA, Lunde PK, Djurovic S, Lyberg T et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005; 289: H708-H714.
23. Loeffler M, Le'negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 2007; 104: 12879-12883.
24. Luo Y, Zhou H, Mizutani M, Mizutani N, Liu C, Xiang R et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res 2005; 65: 3419-3427.
25. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-760.
26. Agorio C, Schreiber F, Sheppard M, Mastroeni P, Fernandez M, Martinez MA et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9: 416-423.
27. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA 2003; 100: 8850-8855.
28. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20(5 Suppl 27): S1-13.
29. Reed JC, Doctor KS, Godzik A. The domains of apoptosis: a genomics perspective. Sci STKE 2004; 2004: re9.